Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D-Reference-Cited by-同舟云学术

Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

Published:2018-09-04 Issue:9 Volume:320 Page:931
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Yazdany Jinoos¹,Dudley R. Adams²,Lin Grace A.²,Chen Randi³,Tseng Chien-Wen⁴

Affiliation:

1. Division of Rheumatology, University of California, San Francisco

2. Center for Healthcare Value, University of California, San Francisco

3. Pacific Health Research and Education Institute, Honolulu, Hawaii

4. Department of Family Practice and Community Health, University of Hawaii, Honolulu

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference6 articles.

1. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.;Yazdany;Arthritis Rheumatol,2015

2. Obstacles to the adoption of biosimilars for chronic diseases.;Hakim;JAMA,2017

3. MulcahyAW, HlavkaJP, CaseSR. Biosimilar cost savings in the United States: initial experience and future potential. https://www.rand.org/pubs/perspectives/PE264.html. Accessed April 9, 2018.

4. Centers for Medicare & Medicaid Services. 2015 Medicare drug spending dashboard. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/2015Medicare.html. Accessed April 9, 2018.

5. Kaiser Family Foundation. The Medicare Part D prescription drug benefit. https://www.kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet/. Accessed April 9, 2018.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acknowledging and addressing real-world challenges to treating immune-related adverse events;Journal for ImmunoTherapy of Cancer;2024-07

2. Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms;Health Affairs;2024-05-01

3. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition;JAMA Health Forum;2024-03-29

4. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024

5. Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study;ACR Open Rheumatology;2023-06-13